The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics

Diana Bautista-Sánchez,1,6 Cristian Arriaga-Canon,1,6 Abraham Pedroza-Torres,2 Inti Alberto De La Rosa-Velázquez,3 Rodrigo González-Barrios,1 Laura Contreras-Espinosa,1 Rogelio Montiel-Manríquez,1 Clementina Castro-Hernández,1 Verónica Fragoso-Ontiveros,4 Rosa María Álvarez-Gómez,4 and Luis A. Herrera1,5

1Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, UNAM, Avenida San Fernando No. 22, Colonia Sección XVI, Tlalpan, CP 14080, Mexico City, Mexico; 2CONACYT-Instituto Nacional de Cancerología, Avenida San Fernando No. 22, Colonia Sección XVI, Tlalpan, CP 14080, Mexico City, Mexico; 3Department of Epigenetics, Max Planck Institute of Immunobiology and Epigenetics, Stühbeweg 51, 79108 Freiburg, Germany; 4Clínica de Cáncer Hereditario, Instituto Nacional de Cancerología, Avenida San Fernando No. 22, Colonia Sección XVI, Tlalpan, CP 14080, Mexico City, Mexico; 5Instituto Nacional de Medicina Genómica, Periférico Sur 4809, Arenal Tepepan, Tlalpan, CP 14610, Mexico City, Mexico.

MicroRNAs are small noncoding transcripts that posttranscriptionally regulate gene expression via base-pairing complementarity. Their role in cancer can be related to tumor suppression or oncogenic function. Moreover, they have been linked to processes recognized as hallmarks of cancer, such as apoptosis, invasion, metastasis, and proliferation. Particularly, one of the first oncomiRs found upregulated in a variety of cancers, such as gliomas, breast cancer, and colorectal cancer, was microRNA-21 (miR-21). Some of its target genes associated with cancer are PTEN (phosphatase and tensin homolog), PDCD4 (programmed cell death protein 4), RECK (reversion-inducing cysteine-rich protein with Kazal motifs), and STAT3 (signal transducer activator of transcription 3). As a result, miR-21 has been proposed as a plausible diagnostic and prognostic biomarker, as well as a therapeutic target for several types of cancer. Currently, research and clinical trials to inhibit miR-21 through anti-miR-21 oligonucleotides and ADM-21 are being conducted. As all of the evidence suggests, miR-21 is involved in carcinogenic processes; therefore, inhibiting it could have effects on more than one type of cancer. However, whether miR-21 can be used as a tissue-specific biomarker should be analyzed with caution. Consequently, the purpose of this review is to outline the available information and recent advances regarding miR-21 as a potential biomarker in the clinical setting and as a therapeutic target in cancer to highlight its importance in the era of precision medicine.

MicroRNAs

In 1993, Ambros et al.1 discovered in Caenorhabditis elegans that the lin-4 gene (currently known as lin-4 microRNA [miRNA]) could decrease the levels of lin-14 protein through antisense complementary binding of the RNA transcripts. Later, other miRNA genes with the same mechanism of action were found in different species, including humans. Thus, miRNAs were established as novel, small regulatory RNA molecules. These noncoding genes are single-stranded structures of 19–25 nt that can be found in intergenic or intragenic regions of the genome.2

As regulatory biomolecules, miRNAs need to be only partially complementary to induce the regulation of a target gene.3 Hence, a single miRNA can regulate a variety of genes, and a single gene can be targeted by many miRNAs.4 As a result, the identification of target genes is a complex process.5 Moreover, due to their broad regulatory activity, miRNAs are involved in a large number of processes, including development,6,7 proliferation,8–10 apoptosis,11,12 metabolism,13,14 differentiation,15 and metastasis,16,17 among others.18 Despite their broad involvement in a variety of processes, miRNA functions can be divided into two types: homeostatic regulation of gene expression and robustness in cellular responses.19 The first type involves the regulation of gene expression through the precise adjustment of the cell’s requirements.20,21 As there are proteins that should be optimally expressed at low levels in certain cell types, miRNAs can fine-tune the expression of these. However, the second type of regulation is present on processes such as cell fate, its differentiation state, and stress responses,22–24 and its main objective is to dampen the protein production of the targeted messenger RNA (mRNA) almost completely.19,25 This regulation ensures accuracy and robustness by repressing the expression of miRNAs that linger from previous cell states or the products of leaky transcription.25
To synthesize a miRNA, a particular biogenesis pathway is followed. The biogenesis of miRNAs starts when RNA polymerase II (for intragenic or intergenic miRNAs)26–28 or RNA polymerase III (for some intergenic miRNAs)29–31 transcribes the miRNA gene and produces a primary transcript (pri-miRNA) with a 5' cap and polyadenylation at the 3' end.32 Subsequently, Drosha (an RNase III), assisted by DGC8 (DiGeorge syndrome critical region 8), cleaves the pri-miRNA sequence, releasing it as a precursor loop of approximately 70 nt called a pre-miRNA.32–35 Furthermore, exportin 5 (XPO5) in the nuclear membrane is capable of exporting the precursor sequences out of the nucleus.35 Outside the nucleus, pre-miRNAs are cleaved by Dicer (an RNase III), aided by TRBP (transactivation response element RNA-binding protein), to become mature miRNAs of approximately 22 nt in length.36–38 Two mature miRNA sequences are produced, one of which is selected as a guide strand on the basis of a hydrogen bonding selection mechanism dependent on Argonaute (AGO) proteins.39 Finally, this complex, along with AGO proteins, forms the RNA-induced silencing complex (RISC) for gene silencing by base pairing to the 3' untranslated region (UTR) of an mRNA.40

Alternatively, the translation repression mechanism is still the subject of debate. Mechanisms inhibiting translation include cap-dependent translation inhibition,41–43 cap-independent translation mechanisms,41,44,45 premature termination (the drop-off theory),42,46,47 and the recruitment of proteolytic enzymes that can degrade a polypeptide as it is being produced.42 mRNA decay is another mechanism of miRNA inhibition in which miRNAs bound to miRNAs accumulate in P-bodies inside the cytoplasm where they are degraded by the 5' to 3' exonuclease activity of Xrn1 (5'-3' exoribonuclease 1).48–50 miRNA biogenesis and repression mechanisms are complex processes that are tightly regulated and have not yet been fully elucidated. Their dynamics and effects are of special interest to have a better understanding of many complex diseases, such as cancer.

miRNAs and Cancer

As reported previously, miRNAs are involved in a variety of processes inside the cell, some of which are considered hallmarks of cancer (e.g., metastasis,16,17 cell proliferation,9,51 apoptosis,11,12). Furthermore, it has been reported that more than 50% of miRNAs are located at fragile sites or regions where deletion or amplification tends to occur in human cancers.52 Accordingly, miRNA expression in cancer cells is dysregulated (more commonly upregulated) in comparison to normal cells.53–55 It has been found that miRNA expression profiles can classify poorly differentiated tumors more successfully than mRNA expression profiles, which highlights their importance in cancer.56–58 These findings were obtained after Lu et al.58 analyzed 17 poorly differentiated tumors with non-diagnostic histologic appearance. Overall, poorly differentiated tumors had lower levels of miRNAs compared with more differentiated tumors. Even at low levels, miRNA profiles could establish a better diagnosis by classifying tumors into 11 categories (including colon, ovary, lung, breast, lymphoblastic lymphoma), unlike the mRNA-based classification.

In particular, miRNAs involved in cancer are divided into two categories: oncogenes (oncomiRs) and tumor suppressors.59 OncomiRs act by promoting tumor development by inhibiting tumor suppressor genes; some examples of these small RNAs are homologous miRNA (miR)-221/222,60 miR-27a,61,62 and miR-21.63–65 In contrast, tumor suppressor miRNAs inhibit oncogenes, thereby suppressing tumor development. Some miRNAs that serve as tumor suppressors are miR-145,66 the let-7 family,67 and miR-205,68,69 In either role, miRNAs have been shown to be crucial for processes considered to be hallmarks of cancer.

miR-21

miR-21 was one of the first mammalian miRNAs identified.28,70 Regarding its structure, miR-21 is found on chromosome 17 (17q.23.1) in the 11th intron of the TMEM49 (transmembrane protein 49) gene, precursor of VMP1 (vacuole membrane protein 1).38,71 It has its own highly conserved promoter.38 In 2008, Fujita et al.72 described a putative promoter region (miPPR-21) containing TATA, GC, and CCAAT boxes, as well as binding sites for activator protein 1 (AP-1), E-26 transformation specific/PD.1 (Ets/PD.1), CCAAT/enhancer-binding protein α (C/EBPα), nuclear factor I (NFI), serum response factor (SRF), p53, and signal transducer activator of transcription 3 (STAT3).73 (Figure 1). When transcribed, the miR-21 gene produces a 3,433-nt long pri-miRNA (pri-miR-21). Subsequently, it is cleaved into a 72-nt-long pre-miRNA loop, which is the source of the miR-21-5p and miR-21-3p mature transcript (21 and 20 nt long, respectively).75

Alternatively, the epigenetic regulation of miR-21 has not been thoroughly studied, but in research conducted by Ferraro et al.,76 it was found that histone posttranslational modifications such as H3K27me3 and H3K9me2 were completely absent, whereas the marks related to active transcription, H3K9-14ac, H3K4me3, and H3K27me3 were completely absent, whereas the marks related to active transcription, H3K9-14ac, H3K4me3, and H3K27ac, were higher on the promoter of miR-21 in cell lines with an epithelial-mesenchymal transition (EMT) phenotype.76 However, further studies are needed to understand the relationship between the miRNA promoter sequence, histone marks, and the expression of miRNAs, particularly miR-21.76

As reported previously, miR-21 is subject to transcriptional regulation, but the mechanisms involved in its posttranscriptional regulation have also been described. For example, in smooth muscle cells, bone morphogenic proteins (BMPs) and transforming growth factor β (TGF-β) stimulate the maturation of miR-21 via the recruitment of SMAD proteins (SMAD1 and SMAD5) are specific for BMPs, and SMAD-3 is specific for TGF-β that stabilize the DROSHA microprocessor complex.77 In another study, miR-21 expression was found to be downregulated in MCF-7 cells when exposed to estradiol. These results indicate that the estrogen receptor is a negative regulator through the inhibition of DROSHA activity.78 Consequently, these studies show that the regulation of miR-21 is a complex process that involves transcriptional and posttranscriptional steps along the biogenesis pathway.
miR-21 has been linked to cell proliferation through some of its targets, such as programmed cell death protein 4 (PDCD4), sprouty RTK signaling antagonist 2 (SPRY2), phosphatase and tensin homolog (PTEN), and reversion-inducing cysteine-rich protein with Kazal motifs (RECK). In pancreatic cancer cells, miR-21 can promote epidermal growth factor (EGF)-induced proliferation by targeting SPRY2, which inhibits growth factor-induced cell proliferation.\textsuperscript{79} Additionally, mechanistic studies have revealed that the signaling pathways that miR-21 targets to modulate cell proliferation are mitogen-activated protein kinase/extracellular receptor kinase (MAPK/ERK) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT).\textsuperscript{79} As in pancreatic cancer, in non-small-cell lung cancer (NSCLC), miR-21 is associated with cell proliferation through PDCD4\textsuperscript{80} and through PTEN and RECK in Gejji squamous cell lung carcinoma (a type of NSCLC).\textsuperscript{81} Overall, miR-21 plays an important role in cell proliferation in diverse types of cancer, including NSCLC and pancreatic cancer, through pathways involved in the carcinogenic process (Figure 2).

**Migration and Invasion**

miR-21 has been identified as a miRNA involved in metastasis and invasion (metasmir).\textsuperscript{82,83} Particularly in breast, prostate, hepatocellular carcinoma, and colon cancer cell lines, it has been found to target genes linked to decreased metastatic potential, such as PDCD4,\textsuperscript{84} metalloproteinase inhibitor 3 (TIMP3),\textsuperscript{85,86} tropomyosin 1 (TPM1),\textsuperscript{87} serpin peptidase inhibitor/clade B (SERPINB5) coding for Maspin,\textsuperscript{88} and PTEN.\textsuperscript{89} In vitro, the overexpression of miR-21 is correlated with the downregulation of TIMP3 and an increase in the invasiveness of melanoma cell lines WM1552c and WM793b but not with migration potential.\textsuperscript{85} Regarding human hepatocellular carcinoma, it was found that miR-21 controls migration and invasion by targeting PTEN.\textsuperscript{63} PTEN can suppress the expression of MMP-9 and MMP-2 through FAK dephosphorylation. As seen here, miR-21 plays an important role in processes that lead to metastasis, such as migration and invasion, not only...
Fas ligand (FASLG), and Ras homolog family member B (RHOB). In summary, miR-21 can influence apoptotic processes through some of its targets and lead to their inhibition, thereby contributing to carcinogenic processes.

**miR-21: A Biomarker for Diagnosis, Prognosis, and Prediction**

As described above, miR-21 is one of the oncomiRs identified that has been linked to carcinogenic processes. Additionally, it has been found to be upregulated in several cancers. These findings highlight the importance of miR-21 as a plausible molecular biomarker for further large-scale studies to validate its clinical application in diagnosis.

As in breast cancer, miR-21 dysregulation can also be used as a diagnostic biomarker for different types of cancer, such as breast, colorectal, and pancreatic cancers. In particular, Iorio et al. found that in breast cancer samples (76 primary tissue samples), miR-21 was progressively upregulated. It was also found to be a plausible sex-independent biomarker, as a study in male breast cancer demonstrated its overexpression. Despite several studies reporting the upregulation of this miRNA in breast cancer, its sensitivity was inconsistent. In 2016, Gao et al. reviewed 11 studies from 10 articles to evaluate this miRNA as a biomarker. They found a pooled sensitivity and specificity of 0.72 and 0.8, respectively. The area under the curve (AUC) of the summary receiver operating characteristic (SROC) was 0.8517. These results were higher than those of other markers, such as carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) (with a sensitivity of 0.48 and 0.39, respectively). Due to its relatively high specificity and sensitivity in comparison with other markers, miR-21 is recommended for further large-scale studies to validate its clinical application in diagnosis.

As previously mentioned, miR-21 is upregulated in many cancers, such as lung, ovarian, breast, stomach, prostate, colon, thyroid, and pancreatic cancers, as well as gliomas (Table 1). Furthermore, miR-21 targets important tumor suppressor genes as well as genes involved in carcinogenesis, such as PTEN, PDCD4, and RECK. As a result, various studies have proposed miR-21 as a potential molecular biomarker for diagnosis, prediction, and prognosis, as well as a new therapeutic target in various types of cancer.

**miR-21 as a Diagnostic Biomarker**

miR-21 has demonstrated its potential as a diagnostic biomarker for different types of cancer, such as breast, colorectal, and pancreatic cancers. In particular, Iorio et al. found that in breast cancer samples (76 primary tissue samples), miR-21 was progressively upregulated. It was also found to be a plausible sex-independent biomarker, as a study in male breast cancer demonstrated its overexpression. Despite several studies reporting the upregulation of this miRNA in breast cancer, its sensitivity was inconsistent. In 2016, Gao et al. reviewed 11 studies from 10 articles to evaluate this miRNA as a biomarker. They found a pooled sensitivity and specificity of 0.72 and 0.8, respectively. The area under the curve (AUC) of the summary receiver operating characteristic (SROC) was 0.8517. These results were higher than those of other markers, such as carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) (with a sensitivity of 0.48 and 0.39, respectively). Due to its relatively high specificity and sensitivity in comparison with other markers, miR-21 is recommended for further large-scale studies to validate its clinical application in diagnosis.

As in breast cancer, miR-21 dysregulation can also be used as a diagnostic biomarker in pancreatic cancer. In an article published in 2017,
it was found that miR-21 is upregulated in the sera of pancreatic cancer patients, with a sensitivity of 0.77 and specificity of 0.8. In this case, the AUC of the SROC for the Asian population was 0.78. The same study recommended the use of circulating miR-21 alone or in combination with carbohydrate antigen 19-9 (CA-19-9) for a better diagnosis of pancreatic cancer, but the authors agreed that further studies are needed to unveil the clinical significance of miR-21. The overexpression of miR-21 is also found in serum samples from patients with colorectal cancer. In this study, the authors proposed a three-miRNA panel for the non-invasive diagnosis of colorectal cancer by the use of miR-21, miR-19a-3p, and miR-425-5p. The authors of this research refer to the high sensitivity and specificity in colorectal cancer serum samples (0.875 and 0.744, respectively) with an area under the ROC curve of 0.88, as found by Wang and Zhang. Furthermore, in another study, circulating miR-21 was analyzed as an early detection biomarker for colorectal cancer and was reported to have a sensitivity and specificity of 0.77 and 0.84, respectively, with an AUC of the ROC of 0.81. Due to its relatively easy detection, miR-21 is proposed as a highly convenient diagnostic biomarker alongside prostate-specific antigen (PSA) and miR-141, with a high value of AUC when graphing sensitivity and specificity of 0.88. In prostate cancer, miR-21 expression, alongside other biomarkers, has been associated with the pathological stage, lymph node metastasis, and extracapsular extension. Analyses have revealed that miR-21 expression could be a predictor of biochemical-free survival (BFS) in prostate cancer patients. In this way, we hypothesize that the role of miR-21 as a diagnosis biomarker can be accompanied by its use as a prognosis biomarker.

miR-21 as a Prognostic Biomarker

Although miR-21 has been found to be dysregulated in many types of cancer, its role as a prognostic biomarker has still not been elucidated, as the results have been inconsistent. Zhou et al. published an article that aimed to investigate the correlation between miR-21 and overall survival (OS) in general cancers. This work demonstrated that miR-21 correlated with poor survival in general carcinomas, with a pool hazard ratio (HR) of 1.91 for OS, 1.42 for disease-free survival (DFS), and 2.2 for recurrence-free survival (RFS) and cancer-specific survival. Interestingly, when divided into subgroups, miR-21 could predict poor OS in gastrointestinal tumors (HR = 1.68), pancreatic cancer (HR = 2.53), lung cancer (HR = 1.59), breast cancer (HR = 2.55), and liver cancer (HR = 1.93). Moreover, poor DFS was observed when miR-21 was elevated in pancreatic cancer (HR of 2.87) and lung cancer (HR = 2.05), and poor RFS and cancer-specific survival were detected in gastrointestinal tumors (HR = 2.5), lung cancer (HR = 2.25), and prostate cancer (HR = 2.04). These results prove that miR-21 plays an important role in general carcinomas, regardless of its origin. More studies have been conducted regarding the role of miR-21 as a prognostic biomarker for colorectal cancer, in which high expression of this miRNA in tissues correlates with poor OS and DFS. Although this miRNA has been linked to the prognosis of many cancers, specific studies are needed to confirm this general association.
and to offer additional information for each type of cancer through non-invasive but highly accurate testing.\textsuperscript{111-113}

**miR-21 as a Predictive Biomarker**

The use of miR-21 as a biomarker is not limited to diagnosis and prognosis, as several studies have uncovered its usefulness as a predictive biomarker in breast, lung, and ovarian cancers, among others. This is particularly important due to the resistance to treatments that some cancers develop. Increased miR-21 levels were linked to resistance to platinum-based chemotherapy in patient samples with NSCLC (stages I–III).\textsuperscript{114} In this study, resistant responders had increased levels of miR-21 compared with sensitive responders. The resistance to platinum due to an increase in miR-21 was attributed to PTEN and BCL2 expression in this case. Although the molecular mechanism remains unclear, it is known that the loss of PTEN leads to increased activity of the AKT and mammalian target of rapamycin (mTOR) pathways. BCL2, which is thought to be indirectly regulated by miR-21, promotes a chemoresistant phenotype in regard to cisplatin.\textsuperscript{115}

Additionally, miR-21 was also found to play a role in the sensitivity to gemcitabine treatment in patients with advanced pancreatic cancer (stages III and IV).\textsuperscript{116} A high level of serum miR-21 was associated with a poor response to gemcitabine in 177 patients because the time to progression after treatment was of only 80 days, compared with 161 days in patients whose expression of miR-21 was low. The authors of the research linked the decreased sensitivity to gemcitabine to apoptosis resistance after treatment, as miR-21 targets Fas/FasL. Moreover, serum miR-21 levels were also found to predict the outcome of HER2-positive breast cancer patients who had received neoadjuvant chemotherapy and trastuzumab.\textsuperscript{117} Increased levels of miR-21 led to worse clinical responses to chemotherapy during neoadjuvant treatment when combined with trastuzumab. In this way, it was found that miRNA levels distinguished between clinical and

![Table 1. miR-21 as a Diagnostic, Prognostic, and Predictive Biomarker in Several Cancers](image-url)

| Cancer          | Expression                  | Function                                                                 | Targets       | Biomarker Type                                                                 | References |
|----------------|-----------------------------|--------------------------------------------------------------------------|---------------|--------------------------------------------------------------------------------|------------|
| Gastric cancer | downregulated in gastric     | promotes cell proliferation and invasion                                  | PTEN, PDCD4,  | early diagnosis and prognosis of lymph node metastasis                         | 134,135    |
|                | juices but upregulated in    |                                                                          | RECK          |                                                                                |            |
|                | gastric cancer tissues       |                                                                          |               |                                                                                |            |
| Colorectal     | upregulated                  | carcinoma-associated fibroblast formation, tumor formation, metastasis   | SMAD7,       | early diagnosis (circulating miR-21), prognosis adjuvant therapy (tissue miR-21), predictor of tumor relapse | 84,136     |
|                |                             |                                                                          | SMAD 6,      |                                                                                |            |
|                |                             |                                                                          | ITGB4,       |                                                                                |            |
|                |                             |                                                                          | PDCD4        |                                                                                |            |
| Glioma         | upregulated                  | cell growth, apoptosis cell proliferation, cancer stem cell differentiation| PTEN, RECK,  | diagnosis (screening)                                                           | 93         |
|                |                             |                                                                          | FasL, PDCD4, |                                                                                |            |
|                |                             |                                                                          | Bcl2          |                                                                                |            |
| Breast cancer  | upregulated                  | cell survival, apoptosis, resistance to systemic therapy                 | PDCD4, TPM1, | diagnosis triple-negative lymph metastasis and grade III                       | 137        |
|                |                             |                                                                          | RTN4          |                                                                                |            |
| Lung cancer    | upregulated                  | apoptosis, cell proliferation, survival, angiogenesis, inhibition of nuclear factor kB (NF-kB) activation | PDCD4, Smad7,| prognosis and diagnosis (OS)                                                   | 95,138     |
|                |                             |                                                                          | Bcl2, EGF,   |                                                                                |            |
|                |                             |                                                                          | Cas8, TGF-β, |                                                                                |            |
|                |                             |                                                                          | RECK          |                                                                                |            |
| Prostate cancer| upregulated                  | motility, invasion, apoptosis, androgen-independent growth               | PDCD4, TPM1, | early diagnosis                                                                 | 107        |
|                |                             |                                                                          | PTEN          |                                                                                |            |

and to offer additional information for each type of cancer through non-invasive but highly accurate testing.\textsuperscript{111-113}
Pacitaxel (Taxol) and a miR-21 inhibitor enhanced chemotherapy of peroxisome proliferator-activated receptor reactive oxygen species (ROS) accumulation by rescuing the expression of miR-21.

In the case of miR-21, antimiRs offer a new therapeutic approach for liver injury and cardiovascular disease. The ability of miRNAs to target multiple genes through miRNA mimics and the inhibition of miRNA function are still some obstacles to address before its clinical application. One of the main concerns is the delivery of miRNA therapeutic molecules, either by the use of miRNA mimics or antimiRs.

### miR-21 as a Therapeutic Target in Clinical Trials

In addition to its use as a potential biomarker in a diverse range of cancers, miR-21 has become of great interest in the field of miRNA therapeutics, an area that intends to use miRNA replacement therapy through miRNA mimics and the inhibition of miRNA function through antimiRs. The ability of miRNAs to target multiple genes that might be altered in a disease gives them an advantage as therapeutic molecules, either by the use of miRNA mimics or antimiRs. In the case of miR-21, antimiRs offer a new therapeutic approach for liver injury and cardiovascular disease. In particular, mouse models with kidney injury have shown that anti-miR-21 reduced reactive oxygen species (ROS) accumulation by rescuing the expression of peroxisome proliferator-activated receptor α (PPARα), and this effect resulted in decreased liver steatosis in mice. Nonetheless, these results are not conclusive, as PPARα might not be the only miR-21 target that has an impact on this network. Although miR-21 appears to be a promising alternative as an anticancer therapy, there are still some obstacles to address before its clinical application. One of the main concerns is the delivery of miRNA therapeutic molecules, as anti-miR-21 has not overcome the tumor microenvironment, and, as a consequence, in vivo targeting of this miRNA has not been completely successful in all cancers.

In cancer therapeutics, miR-21 is an appealing candidate because of all of the carcinogenic processes it has been traced to. In particular, in breast cancer, Mei et al. demonstrated that the combination of paclitaxel (Taxol) and a miR-21 inhibitor enhanced chemotherapeutic effects in breast cancer cells (MCF7). However, this is not the only case where a miR-21 inhibitor has been shown to be efficient; anti-miR-21 has also been shown to reduce tumor size in xenograft mouse models of prostate cancer with an androgen-independent cell line, DU-145. Furthermore, in pancreatic cancer, miR-21 inhibition has been shown to stop tumor growth in an aggressive xenograft mouse model; additionally, in combination with gemcitabine, it can induce tumor regression. The authors hypothesized that an increase in angiogenesis due to the inhibition of miR-21 could enhance the delivery of gemcitabine to the tumor. In view of this information, miR-21 was introduced as a potential therapeutic target in breast cancer and other cancer types, such as prostate and pancreatic cancers, where the regulation of these genes plays an important role in cancer progression.

In fact, clinical trials for suppressing miR-21 are currently being conducted (Table 2). For example, Genzyme is conducting a phase 1 multicenter study where RG-012, a chemically modified oligonucleotide that can bind to miR-21, is being tested in patients with Alport syndrome (ClinicalTrials.gov: NCT03373786). The molecule has proven to decrease the rate of progression of renal fibrosis by inhibiting miR-21. Alternatively, ADM-21, a miR-21 inhibitor, is under assessment in a xenograft mouse model of bladder cancer. Results have shown that ADM-21 effectively decreases bladder cancer growth in vitro and in vivo by inhibiting the miR-21 regulation of the protein phosphatase 2 regulatory subunit Bζ (PPP2R2A), a regulator of the AKT/mTOR pathway. After toxicity studies have concluded, testing this modified oligonucleotide in clinical phase 1 trials is needed.

Finally, an interventional clinical trial is currently being conducted that involves the study of six miRNAs (including miR-21) to determine whether a patient with stage II colon cancer should not receive adjuvant chemotherapy (ClinicalTrials.gov: NCT02466113) according to OS and DFS measurements. Although trials are currently being conducted on miR-21 therapeutics, there are still many therapeutic and biomarker options that have not yet been explored, especially in cancer, where it is one of the most dysregulated miRNAs.

### Challenges for miR-21 as a Biomarker and Therapeutic

Ironically, one of the greatest advantages of miR-21 for its use as a biomarker is also its most difficult challenge: miR-21 has been found to be dysregulated in more than one condition, including several types of cancer. Then, how can this plausible biomarker be specific enough to detect a condition and differentiate among others? This is particularly important because miR-21 has been proposed as a non-invasive circulating biomarker; however, if its dysregulation is so common in many different diseases, its expression pattern might follow broad stress responses in a cell instead of specific conditions. In other words, if miR-21 is involved in many types of cancer, it might confer robustness to the carcinogenic process by dampening the protein production of its targets. If this is the case, miR-21 would not be the best biomarker for a specific cancer. It would instead describe a carcinogenic process occurring in any organ or tissue showing elevated levels of miR-21 in cancer. Therefore, it would be more convenient to use miR-21 as part of a biomarker panel specific for cancer progression.

### Table 2. miR-21 in Clinical Trials and RNA-Based Therapeutics

| Method | Disease | Experimental Models | Status | Reference |
|--------|---------|---------------------|--------|-----------|
| Anti-miR-21 | Alport syndrome | Alport syndrome patients (18-65 years old) | clinical trial phase 1 multicenter study | 125 |
| Anti-miR-21 | bladder cancer | mouse xenograft | preclinical | 126 |
| Anti-miR-21 | cardiovascular disease | C57BL/6 male mice | preclinical | 130-141 |
| Anti-miR-21 | liver injury | bile duct ligation mouse model | preclinical | 142 |
| Anti-miR-21 | pancreatic cancer | Mia PaCa-2 Lucia F1 cells in mice (xenograft model) | preclinical | 124 |
| qRT-PCR | colon cancer stage II | patients with stage II colon cancer (18-65 years old) | interventional clinical trial | 127 |
| Anti-miR-21 | prostate cancer | DU145 cells in nude mice (xenograft model) | preclinical | 143 |
each condition in combination with tissue-specific miRNAs to validate the occurring carcinogenic process and locate the affected tissue.

Another issue that has to be solved in order for miR-21 to become a biomarker is the standardization of methods. Recently, inconsistencies between the expression of several miRNAs measured under the same conditions have been found, such as the analysis made by Gao et al. for miR-21 in breast cancer. This finding was not understood, as miRNAs have become of great interest as biomarkers due to their stability. However, it has been proposed that preprocessing steps make a difference when measuring their expression.

In addition, miR-21-based therapeutics also present challenges. The broad regulation of miRNAs within a cell has been discussed, and miRNAs can have many targets related to different functions. This can have a positive aspect when most targets follow the functions of oncomiRs or tumor suppressors, but when a target gene has functions that can either promote or suppress the carcinogenic process, such as the miR-21 target BCL2, the usefulness of a miRNA-based therapeutic is questioned. Furthermore, only some of the targets of a miRNA have been validated, and cancer is a complex disease. How can we be certain that miRNA therapies will have the results we expect from models? Finally, some other challenges faced by miRNA therapeutics are toxicity and long-term effects, both of which address the fact that antimiRs have to avoid the action of nucleases, but little is known about the toxic metabolites produced by the oligonucleotide that is degraded.

Although miR-21-based biomarkers and therapeutics seem very plausible for use in the near future, there are still challenges to address before approving them. If these challenges are overcome, miR-21 could become one of the first miRNA biomarkers and therapy molecules used for complex and sometimes fatal diseases, such as cancer.

Conclusions

Experimental and clinical evidence points to miR-21 as a key element in cancer development, as it is involved in invasion, metastasis, cell proliferation, and apoptosis. The identification of some of its target genes and their downregulation effects in cancer remains to be fully elucidated. Despite this fact, miR-21 is a promising biomarker for diagnosis, prognosis, and prediction, although its broad function and dysregulation have been linked to more than one type of cancer. Furthermore, in vitro and in vivo studies have shown that its inhibition has positive effects on cancer therapy, which enhances its role as a plausible therapeutic target. Currently, clinical trials and toxicity pharmacokinetic evaluations are being conducted for miR-21 inhibitors, such as ADM-21, as therapeutic molecules.

However, there still exist some limitations for its use, such as the lack of knowledge about dose requirements and its administration. Nevertheless, work on these limitations is currently underway, and important issues, such as the administration and delivery of miRNA mimics and anti-miRs, are being solved. These findings will bring a new era for therapeutics, RNA-based therapeutics, which is especially promising for miRNAs in cancer, where they are especially dysregulated. Low-cost therapy and diagnosis with almost no immune response complications could enhance the use of personalized therapies that could provide all cancer patients with the most effective and specific combination for their sickness. Therefore, to reach the era of RNA therapeutics, two main goals must be achieved: improve the delivery strategies and identify the side effects that these molecules could have on complex diseases.

In conclusion, further information and basic research are required before miR-21 can be used extensively as an approved biomarker and therapeutic target, but its upregulation in a large number of cancers, as well as its relationship with many processes that regulate cancer progression, make it a promising molecule in cancer and in RNA-based therapies.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

We thank the National Cancer Institute of Mexico (INCan) for support. Figures were created with BioRender.com.

REFERENCES

1. Lee, R.C., Feinbaum, R.L., and Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854.
2. Ambros, V., Bartel, B., Bartel, D.P., Burge, C.B., Carrington, J.C., Chen, X., Dreyfuss, G., Eddy, S.R., Griffiths-Jones, S., Marshall, M., et al. (2003). A uniform system for microRNA annotation. RNA 9, 277–279.
3. Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233.
4. Doench, J.G., and Sharp, P.A. (2004). Specificity of microRNA target selection in translational repression. Genes Dev. 18, 504–511.
5. Seitz, H. (2017). Issues in current microRNA target identification methods. RNA Biol. 14, 831–834.
6. Ivey, K.N., and Srivastava, D. (2015). MicroRNAs as developmental regulators. Cold Spring Harb. Perspect. Biol. 7, a008144.
7. Sayed, D., and Abdellatif, M. (2011). MicroRNAs in development and disease. Physiol. Rev. 91, 827–887.
8. Croce, C.M., and Calin, G.A. (2005). miRNAs, cancer, and stem cell division. Cell 122, 6–7.
9. Bueno, M.J., and Malumbres, M. (2011). MicroRNAs and the cell cycle. Biochim. Biophys. Acta 1812, 592–601.
10. Hydbring, P., Wang, Y., Fassl, A., Li, X., Matia, V., Otto, T., Choi, Y.J., Sweeney, K.E., Suski, J.M., Yin, H., et al. (2017). Cell-cycle-targeting microRNAs as therapeutic tools against refractory cancers. Cancer Cell 31, 576–590.e8.
11. Jovanovic, M., and Hengartner, M.O. (2006). miRNAs and apoptosis: RNAs to die for. Oncogene 25, 6176–6187.
12. Su, Z., Yang, Z., Xu, Y., Chen, Y., and Yu, Q. (2015). MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget 6, 8474–8490.
13. Vienberg, S., Geier, J., Madsen, S., and Dalgaard, L.T. (2017). MicroRNAs in metabolism. Acta Physiol. (Oxf.) 219, 346–361.
14. Rottiers, V., and Naïr, A.M. (2012). MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 13, 239–250.
15. Yao, S. (2016). MicroRNA biogenesis and their functions in regulating stem cell potency and differentiation. Biol. Proced. Online 18, 8.
16. Lou, W., Liu, J., Gao, Y., Zhong, G., Chen, D., Shen, J., Bao, C., Xu, L., Pan, J., Cheng, J., et al. (2017). MicroRNAs in cancer metastasis and angiogenesis. Oncotarget 8, 115787–115802.

17. Ma, L. (2016). MicroRNA and metastasis. Adv. Cancer Res. 132, 165–207.

18. Li, S., Liang, Z., Xu, L., and Zou, F. (2012). MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases. Mol. Cell. Biochem. 360, 147–158.

19. Bushati, N., and Cohen, S.M. (2007). MicroRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175–205.

20. Mihailovich, M., Breman, M., Spadotto, V., Musiani, D., Vitale, E., Varano, G., Zambelli, F., Mancuso, F.M., Cairns, D.A., Pavesi, G., et al. (2015). miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat. Commun. 6, 8725.

21. Vian, L., Di Carlo, M., Pelosi, E., Fazi, F., Santoro, S., Cerio, A.M., Boe, A., Rotoli, V., Bili, M., Raccanici, S., et al. (2014). Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death Differ. 21, 290–301.

22. Brenner, J.L., Jasiewicz, K.L., Fahley, A.F., Kemp, B.J., and Abbott, A.L. (2010). Loss of individual microRNAs causes mutant phenotypes in sensitized genetic backgrounds in C. elegans. Curr. Biol. 20, 1321–1325.

23. Alvarez-Saavedra, E., and Horvitz, H.R. (2010). Many families of C. elegans microRNAs are not essential for development or viability. Curr. Biol. 20, 367–373.

24. Li, X., Cassidy, J.J., Reinke, C.A., Fischbock, S., and Carthew, R.W. (2009). A microRNA imparts robustness against environmental fluctuation during development. Cell 137, 273–282.

25. Bartel, D.P., and Chen, C.-Z. (2004). Micromanagers of gene expression: the poten-

20. Mihailovich, M., Breman, M., Spadotto, V., Musiani, D., Vitale, E., Varano, G., Zambelli, F., Mancuso, F.M., Cairns, D.A., Pavesi, G., et al. (2015). miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat. Commun. 6, 8725.

21. Vian, L., Di Carlo, M., Pelosi, E., Fazi, F., Santoro, S., Cerio, A.M., Boe, A., Rotoli, V., Bili, M., Raccanici, S., et al. (2014). Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death Differ. 21, 290–301.

22. Brenner, J.L., Jasiewicz, K.L., Fahley, A.F., Kemp, B.J., and Abbott, A.L. (2010). Loss of individual microRNAs causes mutant phenotypes in sensitized genetic backgrounds in C. elegans. Curr. Biol. 20, 1321–1325.

23. Alvarez-Saavedra, E., and Horvitz, H.R. (2010). Many families of C. elegans microRNAs are not essential for development or viability. Curr. Biol. 20, 367–373.

24. Li, X., Cassidy, J.J., Reinke, C.A., Fischbock, S., and Carthew, R.W. (2009). A microRNA imparts robustness against environmental fluctuation during development. Cell 137, 273–282.

25. Bartel, D.P., and Chen, C.-Z. (2004). Micromanagers of gene expression: the poten-

20. Mihailovich, M., Breman, M., Spadotto, V., Musiani, D., Vitale, E., Varano, G., Zambelli, F., Mancuso, F.M., Cairns, D.A., Pavesi, G., et al. (2015). miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat. Commun. 6, 8725.

21. Vian, L., Di Carlo, M., Pelosi, E., Fazi, F., Santoro, S., Cerio, A.M., Boe, A., Rotoli, V., Bili, M., Raccanici, S., et al. (2014). Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death Differ. 21, 290–301.

22. Brenner, J.L., Jasiewicz, K.L., Fahley, A.F., Kemp, B.J., and Abbott, A.L. (2010). Loss of individual microRNAs causes mutant phenotypes in sensitized genetic backgrounds in C. elegans. Curr. Biol. 20, 1321–1325.

23. Alvarez-Saavedra, E., and Horvitz, H.R. (2010). Many families of C. elegans microRNAs are not essential for development or viability. Curr. Biol. 20, 367–373.

24. Li, X., Cassidy, J.J., Reinke, C.A., Fischbock, S., and Carthew, R.W. (2009). A microRNA imparts robustness against environmental fluctuation during development. Cell 137, 273–282.

25. Bartel, D.P., and Chen, C.-Z. (2004). Micromanagers of gene expression: the poten-

20. Mihailovich, M., Breman, M., Spadotto, V., Musiani, D., Vitale, E., Varano, G., Zambelli, F., Mancuso, F.M., Cairns, D.A., Pavesi, G., et al. (2015). miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat. Commun. 6, 8725.

21. Vian, L., Di Carlo, M., Pelosi, E., Fazi, F., Santoro, S., Cerio, A.M., Boe, A., Rotoli, V., Bili, M., Raccanici, S., et al. (2014). Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death Differ. 21, 290–301.

22. Brenner, J.L., Jasiewicz, K.L., Fahley, A.F., Kemp, B.J., and Abbott, A.L. (2010). Loss of individual microRNAs causes mutant phenotypes in sensitized genetic backgrounds in C. elegans. Curr. Biol. 20, 1321–1325.

23. Alvarez-Saavedra, E., and Horvitz, H.R. (2010). Many families of C. elegans microRNAs are not essential for development or viability. Curr. Biol. 20, 367–373.

24. Li, X., Cassidy, J.J., Reinke, C.A., Fischbock, S., and Carthew, R.W. (2009). A microRNA imparts robustness against environmental fluctuation during development. Cell 137, 273–282.

25. Bartel, D.P., and Chen, C.-Z. (2004). Micromanagers of gene expression: the poten-

20. Mihailovich, M., Breman, M., Spadotto, V., Musiani, D., Vitale, E., Varano, G., Zambelli, F., Mancuso, F.M., Cairns, D.A., Pavesi, G., et al. (2015). miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat. Commun. 6, 8725.
61. Guttila, I.K., and White, B.A. (2009). Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem. 284, 23204–23216.
62. Tang, W., Zhu, J., Su, S., Wu, W., Liu, Q., Su, F., and Yu, F. (2012). miR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS ONE 7, e51702.
63. Meng, F., Hensons, R., Webbe-Janek, H., Ghoshal, K., Iacob, S.T., and Patel, T. (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647–658.
64. Hu, J., Ni, S., Cao, Y., Zhang, T., Wu, T., Yin, X., Lang, Y., and Lu, H. (2016). The Angiogenic effect of microRNA-21 Targeting TIMP3 through the regulation of MMP2 and MMP9. PLoS ONE 11, e0149537.
65. Valeri, N., Gasparini, P., Braccon, C., Paone, A., Lovat, F., Fabbr, M., Sumani, K.M., Alder, H., Amadori, D., Patel, T., et al. (2010). MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. USA 107, 21098–21103.
66. Fuse, M., Nohata, N., Kojima, S., Sakamoto, S., Chiyomaru, T., Kawakami, K., Enokida, H., Nakagawa, M., Naya, Y., Ichikawa, T., and Seki, N. (2011). Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int. J. Oncol. 38, 1093–1101.
67. Mizuno, R., Kawada, K., and Sakai, Y. (2018). The molecular basis and therapeutic potential of Let-7 microRNAs against colorectal cancer. Can. J. Gastroenterol. Hepatitis 2018, 5769591.
68. Gulei, D., Magdo, J., Jurj, A., Raduly, L., Cojocneau-Petric, R., Moldovan, A., Moldovan, C., Florea, A., Pasca, S., Pop, L.-A., et al. (2018). The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression. Cell Death Dis. 9, 66.
69. De Cola, A., Volpe, S., Budani, M.C., Volpe, S., Budani, M.C., Ferracin, M., Lattanzio, R., Turdo, A., Mizuno, R., Kawada, K., and Sakai, Y. (2018). The molecular basis and therapeutic potential of Let-7 microRNAs against colorectal cancer. J. Biol. Chem. 294, 34358–34368.
70. Velli, A., Pann, L., Wu, T., Yang, X., Cao, Y., Zhang, T., Wu, T., Yin, X., Lang, Y., and Lu, H. (2016). The Angiogenic effect of microRNA-21 Targeting TIMP3 through the regulation of MMP2 and MMP9. PLoS ONE 11, e0149537.
71. Rodriguez, R., Mendell, J.T., and Lupold, S.E. (2012). A novel source for miR-21 promoters. Genes Dev. 26, 3183–3185.
72. Klinge, C.M. (2009). Estradiol downregulates miR-21 expression and increases MMP2 and MMP9 expression. J. Biol. Chem. 284, 65807–65812.
73. Fujita, S., Ito, T., Minoguchi, S., Minogiuchi, S., Yamanaka, N., Nakamura, K., and H. (2008). miR-21 gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol. 378, 492–504.
74. Ribas, J., Ni, X., Castaneras, M., Liu, M.M., Esopi, D., Yegnasubramanian, S., Rodriguez, R., Mendell, J.T., and Lupold, S.E. (2012). A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Res. 40, 6821–6833.
75. Osolak, F., Poling, L.I., Wang, Z., Liu, H., Liu, X.S., Roeder, R.G., Zhang, X., Song, J.S., and Fisher, D.E. (2008). Chromatin structure analyses identify miRNA promoters. Genes Dev. 22, 3172–3183.
76. Fujita, S., Ito, T., Minoguchi, S., Minogiuchi, S., Yamanaka, N., Nakamura, K., and H. (2008). miR-21 gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol. 378, 492–504.
77. Madhurum, S., Mummula, S., Asanagi, I., Kumarswamy, R., Nelson, L.D., and Allgayer, H. (2011). Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep. 31, 185–197.
78. Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A., and Enright, A.J. (2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34, D140–D144.
79. Ferraro, A., Kontos, C.K., Boni, T., Bontouanis, I., Siakouli, D., Kosmidou, V., Vlassi, M., Spyridakis, Y., Tsipras, I., Zografos, G., and Pintzas, A. (2014). Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGB4-PDCC4) as predictor of metastatic tumor potential. Epigenetics 9, 129–141.
80. Kumarswamy, R., Vollmann, I., and Thum, T. (2011). Regulation and function of miRNA-21 in health and disease. RNA Biol. 8, 706–713.
81. Wickramasinghe, N.S., Manavalan, T.T., Dougherty, S.M., Rigg, K.A., Li, Y., and Klinge, C.M. (2009). Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37, 2584–2595.
82. Qiu, F., Tong, H., Wang, Y., Tao, J., Wang, H., and Chen, L. (2018). Inhibition of miR-21-5p suppresses high glucose-induced proliferation and angiogenesis of human retinal microvascular endothelial cells by the regulation of AKT and ERK pathways via maspin. Biotechnol. Biochem. 82, 1366–1376.
83. Huang, T.-H., Wu, F., Loeb, G.B., Hsu, R., Heidersbach, A., Brinca, A., Horiciuchi, D., Lebbink, R.J., Mo, Y.-Y., Goga, A., and McManus, M.T. (2009). Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J. Biol. Chem. 284, 15.540–15.545.
84. Hatley, M.E., Patrick, D.M., Garcia, M.R., Richardson, J.A., Bassel-Duby, R., van Rooij, E., and Olson, E.N. (2010). Modulation of K-ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 18, 282–293.
85. Mei, M., Ren, Y., Zhou, X., Yuan, X.B., Han, L., Wang, G.X., Ju, Z., Pu, P.Y., Kang, C.S., and Yao, Z. (2010). Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol. Cancer Res. Treat. 9, 77–86.
86. Peng, Q., Zhang, X., Min, M., Zou, L., Shen, P., and Zou, Y. (2017). The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget 8, 44983–44990.
87. Qu, K., Lin, T., Pang, Q., Liu, T., Wang, Z., Tai, M., Meng, F., Zhang, J., Wan, Y., Mao, P., et al. (2016). Extracellular miRNA-21 as a novel biomarker in glioma: evidence from meta-analysis, clinical validation and experimental investigations. Oncotarget 7, 33994–34010.
88. Subramanian, V.L., Sels-Jones, V.L., Zakharenko, A.A., Romanov, M.N., and Zaraysky, M.T. (2017). Plasma and saliva miR-21 expression in colorectal cancer patients. J. Appl. Genet. 58, 231–237.
89. Zhao, W., Zhao, J.-J., Zhang, L., Xu, Q.-F., Zhao, Y.-M., Shi, X.-Y., and Xu, A.-G. (2015). Serum miR-21 level: a potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int. J. Clin. Exp. Med. 8, 14759–14763.
90. Weber, J.A., Baxter, D.H., Zhang, S., Huang, D.Y., Huang, K.H., Lee, M.J., Galas, D.J., and Wang, K. (2010). The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1763–1741.
97. Xu, X., Liu, Y., Wang, Y., Meng, M., Wang, K., Zang, X., Zhao, S., Sun, X., Cui, L., Pan, L., and Liu, S. (2016). miR-21 and miR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget 7, 84508–84519.

98. Markou, A., Zavridou, M., and Lianidou, E.S. (2016). miRNA-21 as a novel therapeutic target in lung cancer. Lung Cancer (Auckl.) 7, 19–27.

99. Corcoran, C., Fried, A.M., Duffy, M.J., Crown, J., and O’Driscoll, L. (2011). Intracellular and extracellular microRNAs in breast cancer. Clin. Chem. 57, 18–32.

100. Lehmann, U., Streichert, T., Otto, B., Albat, C., Hasemeier, B., Christgen, H., Schipper, E., Hille, U., Kreipe, H.H., and Länger, F. (2010). Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 10, 109.

101. Gao, Y., Cai, Q., Huang, Y., Li, S., Yang, H., Sun, L., Chen, K., and Wang, Y. (2016). MicroRNA-21 as a potential diagnostic biomarker for breast cancer patients: a pooled analysis of individual studies. Oncotarget 7, 34498–34506.

102. Qu, K., Zhang, X., Lin, T., Liu, T., Wang, Z., Liu, S., Zhou, L., Wei, J., Chang, H., Li, K., et al. (2017). Circulating microRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Sci. Rep. 7, 16952.

103. Zhu, M., Huang, Z., Zhu, D., Zhou, X., Shan, X., Qi, L.-W., Wu, L., Cheng, W., Zhu, J., Zhang, L., et al. (2017). A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget 8, 17081–17091.

104. Wang, B., and Zhang, Q. (2012). The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol. 138, 1659–1666.

105. Zhong, H., Li, P., Ju, H., Pesta, M., Kulda, V., Jin, W., Cai, M., Liu, C., Wu, H., Xu, J., et al. (2014). Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis. Cancer Epidemiol. Biomarkers Prev. 23, 2783–2792.

106. Yaman Agaoglu, F., Kovancilar, M., Dizdar, Y., Darendeliler, E., Holdenrieder, S., Mazanec, J., Hausnerova, J., Kren, L., Hermanova, M., et al. (2015). miR-21, miR-21* and miR-155 expression in blood circulation of patients with prostate cancer. Tumour Biol. 36, 5777–5784.

107. Jackson, B.L., Grabowska, A., and Ratan, H.L. (2014). MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. BMC Cancer 14, 930.

108. Melbø-Jørgensen, C., Ness, N., Andersen, S., Valkov, A., Dennem, T., Al-Saad, S., Kiesel, Y., Berg, T., Nordby, Y., Bremnes, R.M., et al. (2014). Stromal expression of miR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6. PLoS ONE 9, e110309.

109. Zhou, X., Wang, X., Huang, Z., Wang, J., Zhu, W., Shu, Y., and Liu, P. (2014). Prognostic value of miR-21 in various cancers: an updating meta-analysis. PLoS ONE 9, e102413.

110. Vychytilova-Faltejskova, P., Kiss, I., Klusova, S., Hlavsa, J., Prochazka, V., Kala, Z., Kutwin, P., Konecki, T., Borkowska, E.M., Traczyk-Borszyńska, E., and Zabludoff, S., Kalluri, R., and Beretta, L. (2015). miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells. Cancer Res. 75, 1859–1867.

111. Thum, T., Gross, C., Fiedler, J., Fischer, T., Kessler, S., Bussen, M., Galuppo, P., Just, S., Rotthauer, W., Frantz, S., et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980–984.

112. Rodrigues, P.M., Rodrigues, C.M.P., and Castro, R.E. (2018). Modulation of liver steatosis by miR-21/PPARα. Cell Death Dis. 9, 121.

113. Yoshizawa, J.M., and Wong, D.T.W. (2013). Salivary microRNAs and oral cancer diagnosis. J. Oral Pathol. Med. 42, 143–159.

114. Li, T., Li, R.-S., Li, Y.-H., Zhong, S., Chen, Y.-Y., Zhang, C.-M., Hu, M.-M., and Shen, Z.-J. (2012). miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J. Urol. 187, 1466–1472.

115. Tiberio, P., Callari, M., Lalka, H., Buscalia, L., and Cordelier, P. (2013). Targeting miR-21 for the therapy of pancreatic cancer. Mol. Ther. 21, 986–994.

116. National Institutes of Health. A Study of RG-012 in subjects with Alport syndrome. https://clinicaltrials.gov/ct2/show/NCT03373786.

117. Drakaki, A., Koutsioumpa, M., O’Brien, N.A., Vorvis, C., Illoseoulou, D., and Slamon, D.J. (2017). A chemically-modified miR-21 inhibitor (ADM-21) as a novel potential therapy in bladder cancer. J. Clin. Oncol. 35 (Suppl.), 335.

118. National Institutes of Health. A 6 microRNA tool for stratifying stage II colon cancer of subjects with receiving adjuvant chemotherapy. https://clinicaltrials.gov/ct2/show/NCT02466113.

119. Haider, B.A., Baras, A.S., McCall, M.N., Hertel, J.A., Cornish, T.C., and Halushka, P.M. (2014). A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS ONE 9, e89565.

120. Wittwer, K.W. (2015). Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin. Chem. 61, 56–63.

121. Iorio, M.V., and Croce, C.M. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4, 143–159.

122. Liu, B., Su, F., Lv, X., Zhang, W., Shang, X., Zhang, Y., and Zhang, J. (2019). Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab. Cancer Chemother. Pharmacol. 84, 1039–1049.

123. Rodrigues, P.M., Rodrigues, C.M.P., and Castro, R.E. (2018). Modulation of liver steatosis by miR-21/PPARα. Cell Death Dis. 9, 121.

124. Rodrigues, P.M., Rodrigues, C.M.P., and Castro, R.E. (2018). Modulation of liver steatosis by miR-21/PPARα. Cell Death Dis. 9, 121.

125. Haider, B.A., Baras, A.S., McCall, M.N., Hertel, J.A., Cornish, T.C., and Halushka, P.M. (2014). A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS ONE 9, e89565.

126. Wittwer, K.W. (2015). Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin. Chem. 61, 56–63.

127. National Institutes of Health. A 6 microRNA tool for stratifying stage II colon cancer of subjects with receiving adjuvant chemotherapy. https://clinicaltrials.gov/ct2/show/NCT02466113.

128. Haider, B.A., Baras, A.S., McCall, M.N., Hertel, J.A., Cornish, T.C., and Halushka, P.M. (2014). A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS ONE 9, e89565.

129. Wittwer, K.W. (2015). Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin. Chem. 61, 56–63.
138. Bica-Pop, C., Cojoaneanu-Petric, R., Magdlo, L., Raduly, L., Gulei, D., and Berindan-Neagoe, I. (2018). Overview upon miR-21 in lung cancer: focus on NSCLC. Cell. Mol. Life Sci. 75, 3539–3551.

139. Gu, G.-L., Xu, X.-L., Sun, X.-T., Zhang, J., Guo, C.-F., Wang, C.-S., Sun, B., Guo, G.-L., Ma, K., Huang, Y.-Y., et al. (2015). Cardioprotective effect of microRNA-21 in murine myocardial infarction. Cardiovasc. Ther. 33, 109–117.

140. Yang, L., Wang, B., Zhou, Q., Wang, Y., Liu, X., Liu, Z., and Zhan, Z. (2018). MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7. Cell Death Dis. 9, 769.

141. Yuan, J., Chen, H., Ge, D., Xu, Y., Xu, H., Yang, Y., Gu, M., Zhou, Y., Zhu, J., Ge, T., et al. (2017). MiR-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7. Cell. Physiol. Biochem. 42, 2207–2219.

142. Afonso, M.B., Rodrigues, P.M., Simão, A.L., Gaspar, M.M., Carvalho, T., Borralho, P., Batailes, J.M., Castro, R.E., and Rodrigues, C.M.P. (2018). miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. Cell Death Differ. 25, 857–872.

143. Namekawa, T., Ikeda, K., Horige-Inoue, K., and Inoue, S. (2019). Application of prostate cancer models for preclinical study: advantages and limitations of cell lines, patient-derived xenographs, and three-dimensional culture of patient-derived cells. Cells 8, E74.

144. Zhou, X., and Wang, T. (2012). Using the Wash U Epigenome Browser to examine genome-wide sequencing data. Curr. Protoc. Bioinformatics 40, 10.10.1–10.10.14.

145. Löffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermüller, J., Kretzschmar, A.K., Burger, R., Gramatikis, M., Blumert, C., Bauer, K., et al. (2007). Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110, 1330–1333.

146. Kwak, H.-J., Kim, Y.-J., Chun, K.-R., Woo, Y.M., Park, S.-J., Jeong, J.-A., Jo, S.H., Kim, T.H., Min, H.S., Chae, J.S., et al. (2011). Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 30, 2433–2442.

147. Leite, K.R.M., Reis, S.T., Viana, N., Morais, D.R., Moura, C.M., Silva, I.A., Pontes, J., Jr., Katz, B., and Srougi, M. (2015). Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer. J. Cancer 6, 292–301.

148. Gao, M., Patel, R., Ahmad, I., Fleming, I., Edwards, J., McCracken, S., Sahadevan, K., Seywright, M., Norman, J., Sansom, O., and Leung, H.Y. (2012). SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Mol. Med. 4, 776–790.

149. Wietecha, M.S., Chen, L., Ranzer, M.J., Anderson, K., Ying, C., Patel, T.B., and DiPietro, L.A. (2011). Sprouty2 downregulates angiogenesis during mouse skin wound healing. Am. J. Physiol. Heart Circ. Physiol. 300, H459–H467.

150. Zhang, X., Tang, N., Hadden, T.J., and Rishi, A.K. (2011). Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 1813, 1978–1986.

151. Morishii, T., Kawai, Y., Komori, H., Rokutanda, S., Eguchi, Y., Tsujimoto, Y., Ashahina, I., and Komori, T. (2014). Bcl2 deficiency activates FoxO through Akt inactivation and accelerates osteoblast differentiation. PLoS ONE 9, e86629.

152. Memmott, R.M., and Dennis, P.A. (2009). Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell. Signal. 21, 656–664.

153. Zhou, H., and Huang, S. (2011). Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci. 12, 30–42.

154. Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R.M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D.B., et al. (2001). The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789–800.

155. Takahashi, C., Sheng, Z., Horan, T.P., Kitayama, H., Maki, M., Hitomi, K., Kitaura, Y., Takai, S., Sasahara, R.M., Horimoto, A., et al. (1998). Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. USA 95, 13221–13226.

156. Miller, M.A., Sullivan, R.J., and Lauffenburger, D.A. (2017). Molecular pathways: receptor ectodomain shedding in treatment, resistance, and monitoring of cancer. Clin. Cancer Res. 23, 623–629.

157. Campbell, K.J., and Tait, S.W.G. (2018). Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 8, 180002.

158. Shen, L., Ling, M., Li, Y., Xu, Y., Zhou, Y., Ye, J., Pang, Y., Zhao, Y., Jiang, R., Zhang, X., and Liu, Q. (2013). Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformation. PLoS ONE 8, e57652.